Impact ledger
Liquidia Corporation (LQDA): the developments shaping its investment case
Follow the evidence affecting Liquidia Corporation. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Liquidia Corporation · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-14 · 9 reports
Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs
Channel: Direct product adoption vs. legal uncertainty. The patient milestone is positive for product traction, but the ongoing litigation introduces significant downside risk.
mixed· 1-3m
2026-09-12 · 5 reports
Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs
Channel: Direct commercial performance vs. legal overhang
mixed· 3-12m
2026-09-03
Liquidia Corp Receives FDA Fast Track Designation for YUTREPIA
Channel: Regulatory acceleration, reduced development risk, potential for earlier market entry and increased market access.
Bullish· 3-12m
Event impact log
15 events mapped to LQDA since 2026-09-03. Evidence through 2026-09-14.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-14 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs | Direct product adoption vs. legal uncertainty. The patient milestone is positive for product traction, but the ongoing litigation introduces significant downside risk. | mixed | 1-3m | 0.80 |
| 2026-09-14 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues | Direct competition, patent litigation outcome, market penetration | mixed | 3-12m | 0.80 |
| 2026-09-13 | Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit | Direct impact on product commercialization potential and legal expenses. Patient growth is positive, but litigation creates significant uncertainty. | mixed | 3-12m | 0.70 |
| 2026-09-13 | Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit | Direct commercial performance vs. legal risk | mixed | 3-12m | 0.70 |
| 2026-09-13 | Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle | Direct impact on product revenue potential, legal expenses, and investor sentiment due to ongoing patent litigation and market share competition. | mixed | 3-12m | 0.80 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists | Product adoption exceeding expectations, offset by ongoing litigation costs and uncertainty. | mixed | 1-3m | 0.80 |
| 2026-09-12 | Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs | Direct commercial performance vs. legal overhang | mixed | 3-12m | 0.70 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on Stock | Direct impact on product revenue potential and legal expenses. Patent litigation outcome is a significant binary event. | mixed | 3-12m | 0.80 |
| 2026-09-12 | Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigation | Direct commercial performance vs. legal overhang. Patient growth indicates strong market penetration, but litigation creates uncertainty. | mixed | 1-3m | 0.80 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues | Direct impact on product adoption metrics, offset by ongoing legal uncertainty. | mixed | 1-3m | 0.80 |
| 2026-09-12 | Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms | Direct product adoption vs. ongoing litigation risk. Strong commercial traction provides fundamental support, but legal uncertainty creates volatility. | mixed | 1-3m | 0.80 |
| 2026-09-12 | Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers | Direct operational performance (patient adoption) offset by ongoing legal risk and market sentiment. | mixed | 3-12m | 0.70 |
| 2026-09-12 | Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation looms | Direct operational performance (patient growth) offset by significant legal/litigation risk. | mixed | 3-12m | 0.70 |
| 2026-09-12 | Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fight | Direct impact on commercial revenue potential and legal expenses. Patient adoption is positive, but patent litigation creates significant uncertainty. | mixed | 3-12m | 0.80 |
| 2026-09-03 | Liquidia Corp Receives FDA Fast Track Designation for YUTREPIA | Regulatory acceleration, reduced development risk, potential for earlier market entry and increased market access. | Bullish | 3-12m | 0.80 |
Continue this research
Build your Liquidia Corporation investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the LQDA entity page →